Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man
- PMID:12236626
- DOI: 10.1177/026988110201600303
Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man
Abstract
There is evidence for a specific impairment of human vigilance following enhancement of serotonergic activity by antidepressant drugs. In the present study, we investigated the putative role of serotonergic-dopaminergic interactions in diminished vigilance by comparing the attentional effects of sertraline, a selective serotonin reuptake inhibitor (SSRI) with additional mild dopamine stimulating effects, with those of paroxetine, a SSRI without dopamine activity, using a placebo-controlled, double-blind, three-way cross-over design. Twenty-one (of 24) healthy middle-aged subjects completed the three treatment periods of 2 weeks in which sertraline (50 mg, days 1-7; 100 mg, days 8-14), paroxetine (20 mg, days 1-7; 40 mg, days 8-14) and placebo were administered. Vigilance (Mackworth Clock Test), selective (Stroop, Dichotic Listening) and divided attention (Dichotic Listening) were assessed at baseline and on days 7 and 14 of each treatment period. Selective and divided attention were unaffected by SSRI treatment. Subchronic administration of paroxetine impaired vigilance performance at each investigated dose. Sertraline did not produce a significant decline in vigilance performance, presumably due to its concomitant effects on dopamine activity, counteracting the negative effects of serotonin on dopamine neurotransmission. It is concluded that a serotonergically mediated reduction of dopamine activity plays an important role in the reduction of human vigilance following SSRI administration.
Similar articles
- Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment.Riedel WJ, Eikmans K, Heldens A, Schmitt JA.Riedel WJ, et al.J Psychopharmacol. 2005 Jan;19(1):12-20. doi: 10.1177/0269881105048887.J Psychopharmacol. 2005.PMID:15671124Clinical Trial.
- Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC.Fava M, et al.J Clin Psychiatry. 2000 Nov;61(11):863-7. doi: 10.4088/jcp.v61n1109.J Clin Psychiatry. 2000.PMID:11105740Clinical Trial.
- Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI.Ahrold TK, Meston CM.Ahrold TK, et al.J Sex Marital Ther. 2009;35(4):311-9. doi: 10.1080/00926230902851322.J Sex Marital Ther. 2009.PMID:19466669Free PMC article.Clinical Trial.
- Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.Grimsley SR, Jann MW.Grimsley SR, et al.Clin Pharm. 1992 Nov;11(11):930-57.Clin Pharm. 1992.PMID:1464219Review.
- Treating functional impairment of autism with selective serotonin-reuptake inhibitors.Moore ML, Eichner SF, Jones JR.Moore ML, et al.Ann Pharmacother. 2004 Sep;38(9):1515-9. doi: 10.1345/aph.1D543. Epub 2004 Aug 3.Ann Pharmacother. 2004.PMID:15292500Review.
Cited by
- Pharmacological Manipulations of Physiological Arousal and Sleep-Like Slow Waves Modulate Sustained Attention.Pinggal E, Dockree PM, O'Connell RG, Bellgrove MA, Andrillon T.Pinggal E, et al.J Neurosci. 2022 Oct 26;42(43):8113-8124. doi: 10.1523/JNEUROSCI.0836-22.2022. Epub 2022 Sep 15.J Neurosci. 2022.PMID:36109167Free PMC article.Clinical Trial.
- Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good.Andrews PW, Thomson JA Jr, Amstadter A, Neale MC.Andrews PW, et al.Front Psychol. 2012 Apr 24;3:117. doi: 10.3389/fpsyg.2012.00117. eCollection 2012.Front Psychol. 2012.PMID:22536191Free PMC article.
- A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression.Knorr U, Vinberg M, Gade A, Winkel P, Gluud C, Wetterslev J, Gether U, Kessing L.Knorr U, et al.Ther Adv Psychopharmacol. 2011 Oct;1(5):133-44. doi: 10.1177/2045125311422591.Ther Adv Psychopharmacol. 2011.PMID:23983938Free PMC article.
- Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan.Then CK, Chi NF, Chung KH, Kuo L, Liu KH, Hu CJ, Shen SC, Lin YK.Then CK, et al.PLoS One. 2017 Apr 6;12(4):e0175187. doi: 10.1371/journal.pone.0175187. eCollection 2017.PLoS One. 2017.PMID:28384235Free PMC article.
- Neural response to eye contact and paroxetine treatment in generalized social anxiety disorder.Schneier FR, Pomplun M, Sy M, Hirsch J.Schneier FR, et al.Psychiatry Res. 2011 Dec 30;194(3):271-278. doi: 10.1016/j.pscychresns.2011.08.006. Epub 2011 Nov 1.Psychiatry Res. 2011.PMID:22047726Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources